Entrada Therapeutics Inc
NASDAQ:TRDA
Entrada Therapeutics Inc
NASDAQ:TRDA
Price:
12.45 USD
0.73%
Market Closed
Updated:
Apr 28, 2024
Entrada Therapeutics Inc
Net Income (Common)
|
Entrada Therapeutics Inc
Net Income (Common) Peer Comparison
Comparables:
ABBV
GILD
AMGN
VRTX
REGN
Competitive Net Income (Common) Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Entrada Therapeutics Inc
NASDAQ:TRDA
|
Net Income (Common)
-$6.7m
|
CAGR 3-Years
37%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Net Income (Common)
$4.8B
|
CAGR 3-Years
2%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
2%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Net Income (Common)
$5.7B
|
CAGR 3-Years
258%
|
CAGR 5-Years
1%
|
CAGR 10-Years
6%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Net Income (Common)
$6.7B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
3%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Net Income (Common)
$3.6B
|
CAGR 3-Years
10%
|
CAGR 5-Years
12%
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Net Income (Common)
$4B
|
CAGR 3-Years
4%
|
CAGR 5-Years
10%
|
CAGR 10-Years
25%
|
See Also
What is Entrada Therapeutics Inc's Net Income (Common)?
Net Income (Common)
-6.7m
USD
-6.7m
USD
Based on the financial report for Dec 31, 2023, Entrada Therapeutics Inc's Net Income (Common) amounts to -6.7m USD.
What is Entrada Therapeutics Inc's Net Income (Common) growth rate?
Net Income (Common) CAGR 3Y
37%
37%
Over the last year, the Net Income (Common) growth was 93%. The average annual Net Income (Common) growth rates for Entrada Therapeutics Inc have been 37% over the past three years .
You don't have any saved screeners yet
